Edward E Manche, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Manche’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G17270 · Current
Licensed to practise in California · since 1969 · expires 2027-08-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$11,277
Medicare paid this office $11,277 for 58 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 27 | $2,265 | $50 |
| Return visit (30+ min) | 15 | $1,231 | $82 |
| Ct scan of cornea | 51 | $1,046 | $16 |
Who their Medicare patients are
58 Original Medicare patients in 2024. Average age 70 · Women 41% · Also on Medicaid 21% · Health risk score 0.76. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 48% · Coronary heart disease 29% · Diabetes 21%.
The office billed $42,854, Medicare allowed $15,348 and paid $11,277; for 175 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 58 | 175 | 70 | 0.76 | $42,854 | $11,277 |
| 2023 | 52 | 152 | 72 | 0.81 | $34,851 | $10,063 |
| 2022 | 38 | 94 | 73 | 0.87 | $10,909 | $4,943 |
| 2021 | 47 | 92 | 72 | 0.74 | $14,974 | $5,432 |
| 2020 | 37 | 79 | 72 | 0.90 | $22,808 | $4,820 |
| 2019 | 58 | 106 | 73 | 1.00 | $28,582 | $7,146 |
| 2018 | 47 | 72 | 75 | 1.17 | $12,804 | $4,783 |
| 2017 | 62 | 101 | 72 | 0.95 | $28,742 | $6,628 |
| 2016 | 51 | 82 | 71 | 0.99 | $23,829 | $4,727 |
| 2015 | 25 | 48 | 72 | 1.08 | $36,702 | $5,772 |
| 2014 | 26 | 37 | 72 | 0.93 | $3,998 | $912 |
| 2013 | 39 | 52 | 74 | 0.87 | $13,660 | $2,760 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Short return visit (20+ min) | 24 | $2,358 | $56 |
| Return visit (30+ min) | 14 | $1,199 | $80 |
| Ct scan of cornea | 41 | $914 | $17 |
2022: 3 services
| New patient visit (45+ min) | 14 | $1,736 | $124 |
| Short return visit (20+ min) | 16 | $1,370 | $60 |
| Ct scan of cornea | 32 | $753 | $18 |
2021: 3 services
| Short return visit (20+ min) | 21 | $1,248 | $50 |
| Return visit (30+ min) | 13 | $1,177 | $84 |
| Ct scan of cornea | 29 | $543 | $16 |
2020: 3 services
| Return visit (30+ min) | 13 | $811 | $58 |
| Short return visit (20+ min) | 16 | $765 | $42 |
| Ct scan of cornea | 21 | $346 | $14 |
2019: 3 services
| Return visit (30+ min) | 17 | $1,148 | $64 |
| Short return visit (20+ min) | 21 | $1,015 | $44 |
| Ct scan of cornea | 23 | $410 | $15 |
2018: 4 services
| New patient visit (45+ min) | 14 | $1,383 | $99 |
| Return visit (30+ min) | 13 | $989 | $71 |
| Short return visit (20+ min) | 15 | $783 | $46 |
| Ct scan of cornea | 15 | $283 | $18 |
2017: 5 services
| Return visit (30+ min) | 25 | $1,744 | $65 |
| New patient visit (45+ min) | 11 | $1,152 | $105 |
| Short return visit (20+ min) | 17 | $776 | $39 |
| New patient visit (30+ min) | 14 | $679 | $48 |
| Ct scan of cornea | 15 | $132 | $9 |
2016: 3 services
| Short return visit (20+ min) | 21 | $938 | $41 |
| New patient visit (30+ min) | 11 | $731 | $66 |
| Ct scan of cornea | 18 | $331 | $17 |
2015: 1 service
| Short return visit | 14 | $360 | $22 |
2014: 1 service
| Short return visit | 12 | $201 | $17 |
2013: 2 services
| New patient visit (15+ min) | 14 | $609 | $43 |
| Short return visit | 14 | $322 | $21 |
Medicaid work
$4,872 in 2024
Medicaid paid $4,872 for 219 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| COMPUTERIZED CORNEAL TOPOGRAPHY UNI/BI W/I&R | 219 | $4,872 |
| 2024 | 219 | 1 | 25 | $4,872 |
| 2023 | 303 | 2 | 21 | $9,545 |
| 2022 | 215 | 2 | 25 | $6,363 |
| 2021 | 65 | 2 | 14 | $1,675 |
| 2020 | 53 | 1 | 14 | $2,632 |
See the largest Medicaid services in earlier years
2023
| COMPUTERIZED CORNEAL TOPOGRAPHY UNI/BI W/I&R | 193 | $4,855 |
| Return visit (30+ min) | 110 | $4,690 |
2022
| COMPUTERIZED CORNEAL TOPOGRAPHY UNI/BI W/I&R | 136 | $3,210 |
| Return visit (30+ min) | 79 | $3,153 |
2021
| COMPUTERIZED CORNEAL TOPOGRAPHY UNI/BI W/I&R | 52 | $1,208 |
| Return visit (30+ min) | 13 | $467 |
2020
| Return visit (30+ min) | 53 | $2,632 |
Drugs they prescribed that Part D paid
$749
Pharmacies billed $749 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
15 generic and 16 brand-name prescriptions · $749 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 16 | $410 | $26 |
| Moxifloxacin | 13 | $313 | $24 |
Year by year
| 2024 | 31 | 11 | None | 52% | $749 |
| 2023 | 26 | None | None | 50% | $2,615 |
| 2022 | 28 | None | None | 57% | $4,909 |
| 2021 | 13 | None | None | None | $4,161 |
| 2020 | 24 | None | None | 63% | $4,621 |
| 2019 | 35 | 13 | None | 54% | $4,144 |
| 2018 | 34 | 11 | None | 62% | $2,300 |
| 2017 | 50 | 16 | None | 68% | $6,765 |
| 2016 | 40 | 14 | None | 78% | $4,114 |
| 2015 | 39 | 11 | None | 62% | $2,311 |
| 2014 | 20 | None | None | 55% | $1,457 |
| 2013 | 39 | None | None | 79% | $3,918 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Prednisolone Acetate | 11 | $389 | $35 |
2018: 1 drug
| Prednisolone Acetate | 13 | $463 | $36 |
2017: 1 drug
| Prednisolone Acetate | 13 | $666 | $51 |
2016: 1 drug
| Prednisolone Acetate | 12 | $574 | $48 |
2015: 1 drug
| Prednisolone Acetate | 13 | $542 | $42 |
2013: 1 drug
| Prednisolone Acetate | 17 | $347 | $20 |
Money from drug and device companies
$14,655 in 2025
| 2025 | 4 | 28 | $12,025 | $14,655 |
| 2024 | 4 | 18 | $7,275 | $8,094 |
| 2023 | 3 | 18 | $9,700 | $10,851 |
| 2022 | 3 | 14 | $13,594 | $14,272 |
| 2021 | 7 | 23 | $15,969 | $16,711 |
| 2020 | 3 | 5 | None | $324 |
| 2019 | 6 | 19 | $12,450 | $13,280 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
RxSight Inc
$198,737
Held by this doctor · 2023, 2022, 2021, 2020 · Stock
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Glaukos | Epioxa | $13,094 | 15 payments
|
| Johnson & Johnson Surgical Vision | Star S4 Ir | $1,350 | 4 payments
|
| Alcon Vision | Wavelight Sightmap | $176 | 8 payments
|
| Carl Zeiss Meditec USA | Visumax | $36 | 1 payment
|
See all 28 published payments
| Johnson & Johnson Surgical Vision | Consulting · 2025-12-15 | None | $1,100 |
| Alcon Vision | Meals · 2025-11-19 | Wavelight Sightmap | $5 |
| Glaukos | Meals · 2025-10-30 | Kxl System (Not Refurbished) | $54 |
| Alcon Vision | Meals · 2025-10-18 | Wavelight Sightmap | $34 |
| Glaukos | Meals · 2025-10-18 | Kxl System (Not Refurbished) | $26 |
| Johnson & Johnson Surgical Vision | Meals · 2025-10-17 | Star S4 Ir | $94 |
| Glaukos | Consulting · 2025-10-15 | Epioxa | $8,075 |
| Glaukos | Travel · 2025-10-15 | Epioxa | $140 |
| Johnson & Johnson Surgical Vision | Meals · 2025-09-11 | Star S4 Ir | $74 |
| Glaukos | Meals · 2025-09-03 | Travoprost Intraocular Implant - Idose | $353 |
| Glaukos | Travel · 2025-09-03 | Travoprost Intraocular Implant - Idose | $1,113 |
| Alcon Vision | Meals · 2025-08-26 | Wavelight Sightmap | $12 |
| Glaukos | Meals · 2025-08-15 | Photrexa Viscous and Photrexa | $46 |
| Alcon Vision | Meals · 2025-08-12 | Wavelight Sightmap | $14 |
| Glaukos | Meals · 2025-07-10 | Photrexa Viscous and Photrexa | $6 |
| Glaukos | Meals · 2025-07-09 | Photrexa Viscous and Photrexa | $46 |
| Glaukos | Meals · 2025-06-30 | Photrexa Viscous and Photrexa | $53 |
| Glaukos | Consulting · 2025-06-11 | None | $2,850 |
| Alcon Vision | Meals · 2025-05-21 | Clareon | $31 |
| Alcon Vision | Meals · 2025-05-21 | Clareon | $12 |
| Alcon Vision | Meals · 2025-04-27 | None | $35 |
| Glaukos | Meals · 2025-04-26 | Photrexa Viscous and Photrexa | $114 |
| Glaukos | Travel · 2025-04-26 | Photrexa Viscous and Photrexa | $15 |
| Johnson & Johnson Surgical Vision | Meals · 2025-04-25 | Star S4 Ir | $83 |
| Glaukos | Meals · 2025-04-04 | Photrexa Viscous and Photrexa | $157 |
| Alcon Vision | Meals · 2025-03-06 | Wavelight Ex500 Excimer Laser | $32 |
| Glaukos | Meals · 2025-01-22 | Kxl System (Not Refurbished) | $46 |
| Carl Zeiss Meditec USA | Gift · 2025-01-01 | Visumax | $36 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $8,094
| Johnson & Johnson Surgical Vision | Star S4 Ir | $7,552 | 8 payments
|
| Alcon Vision | Argos | $296 | 4 payments
|
| Glaukos | Ce-Marked Kxla System | $179 | 5 payments
|
| Bausch & Lomb Americas | Victus | $68 | 1 payment
|
2023: $10,851
| Johnson & Johnson Surgical Vision | Star S4 Ir | $10,341 | 12 payments
|
| Alcon Vision | Clareon | $386 | 3 payments
|
| Glaukos | Kxl System (Not Refurbished) | $124 | 3 payments
|
2022: $14,272
| Johnson & Johnson Surgical Vision | Star S4 Ir | $13,940 | 10 payments
|
| Alcon Vision | Acrysof Iq Panoptix Uv Iol | $235 | 2 payments
|
| Bausch & Lomb Americas | Victus | $97 | 2 payments
|
2021: $16,711
| Johnson & Johnson Surgical Vision | Idesign Rs | $15,653 | 13 payments
|
| Glaukos | Istent | $606 | 3 payments
|
| Alcon Vision | Acrysof Iq Panoptix | $258 | 3 payments
|
| Tissuetech | Prokera | $121 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Victus | $32 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $26 | 1 payment
|
| RxSight | Light Adjustable Lens (Lal) and Light Delivery Device (Ldd) | $15 | 1 payment
|
2020: $324
| Alcon Vision | Acrysof Iq Panoptix | $164 | 1 payment
|
| Carl Zeiss Meditec | Mel 90 | $117 | 2 payments
|
| Johnson & Johnson Surgical Vision | None | $43 | 2 payments
|
2019: $13,280
| Johnson & Johnson Surgical Vision | One Series Ultra Iol Delivery System | $10,567 | 9 payments
|
| Avedro | None | $2,250 | 1 payment
|
| Alcon Vision | Centurion | $211 | 2 payments
|
| Johnson & Johnson Vision Care | None | $99 | 1 payment
|
| Carl Zeiss Meditec | Opmi Lumera | $88 | 3 payments
|
| Bausch & Lomb a division of Bausch Health US | Victus | $64 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Johnson & Johnson Surgical Vision, Inc. · A Phased, Prospective, Multi-Center Study of the Elita System for the Reduction Or Elimination of Myopic Refractive Errors With Or Without Astigmatism · 2023 | Their institution | $351,299 |
| Johnson & Johnson Surgical Vision, Inc. · A Prospective Randomized Comparison of Topography-Guided Lasik Surgery To Wavefront-Guided Lasik Surgery · 2023 | Their institution | $172,000 |
| Johnson & Johnson Surgical Vision, Inc. · A Prospective Randomized Comparison of Topography-Guided Lasik Surgery To Wavefront-Guided Lasik Surgery · 2022 | Their institution | $153,584 |
| Johnson & Johnson Surgical Vision, Inc. · A Phased, Prospective, Multi-Center Study of the Elita System for the Reduction Or Elimination of Myopic Refractive Errors With Or Without Astigmatism · 2024 | Their institution | $140,788 |
| Johnson & Johnson Surgical Vision, Inc. · A Non-Treatment Clinical Evaluation of the Elita Single Piece Patient Interface for Docking Procedure With the Elita · 2025 | Their institution | $100,971 |
| Johnson & Johnson Surgical Vision, Inc. · A Phased, Prospective, Multi-Center Study of the Elita System for the Reduction Or Elimination of Myopic Refractive Errors With Or Without Astigmatism · 2025 | Their institution | $85,600 |
| Carl Zeiss Meditec, Inc. · A Prospective Multicenter Clinical Study To Evaluate the Safety and Effectiveness of the Mel 90 Excimer Laser Using Lasik (Laser in Situ Keratomileusis) for the Correction of Myopia, Hyperopia, Astigmatism and Mixed Astigmatism. · 2020 | Their institution | $80,144 |
| Johnson & Johnson Surgical Vision, Inc. · A Prospective Randomized Comparison of Smile Surgery and Wavefront Guided Lasik Surgery · 2020 | Their institution | $63,903 |
| Alcon Research LLC · A Prospective Study Analyzing Changes in Corneal Topography, Aberrometry and Corneal Epithelial Thickness Maps Over A One Year Period in Patients Undergoing Bilateral Topography-Guided Lasik Surgery · 2021 | Their institution | $60,250 |
| Avedro Inc. · Photrexa · 2019 | Their institution | $46,635 |
| Carl Zeiss Meditec, Inc. · A Prospective Multicenter Clinical Study To Evaluate the Safety and Effectiveness of the Mel 90 Excimer Laser Using Lasik (Laser in Situ Keratomileusis) for the Correction of Myopia, Hyperopia, Astigmatism and Mixed Astigmatism. · 2021 | Their institution | $40,110 |
| Novartis Pharmaceuticals Corporation · A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study To Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 Mg/Ml and 15 Mg/Ml) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced · 2022 | Their institution | $31,637 |
| Johnson & Johnson Surgical Vision, Inc. · A Prospective Randomized Comparison of Smile Surgery and Wavefront Guided Lasik Surgery · 2021 | Their institution | $31,230 |
| Novartis Pharmaceuticals Corporation · A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study To Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 Mg/Ml and 15 Mg/Ml) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (Prk) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries · 2021 | Their institution | $31,012 |
| Alcon Research LLC · A Prospective Study Analyzing Changes in Corneal Topography, Aberrometry and Corneal Epithelial Thickness Maps Over A One Year Period in Patients Undergoing Bilateral Topography-Guided Lasik Surgery · 2019 | Their institution | $24,100 |
| Johnson & Johnson Surgical Vision, Inc. · A Non Treatment Clinical Evaluation of the Docking Procedure Using Cheetah Beta 2a System and Cheetah Patient Interface · 2021 | This clinician | $22,650 |
| Johnson & Johnson Surgical Vision, Inc. · A Non-Treatment Clinical Evaluation of the Elita Single Piece Patient Interface (Pi) for Docking Procedure With the Elita System · 2024 | Their institution | $17,459 |
| Johnson & Johnson Surgical Vision, Inc. · A Phased, Prospective, Multi-Center Study of the Elita System for the Reduction Or Elimination of Myopic Refractive Errors With Or Without Astigmatism · 2022 | Their institution | $17,459 |
| Carl Zeiss Meditec, Inc. · A Prospective Randomized Comparison of Fellow Eyes Undergoing Lasik With Intralase Ifs 150 Versus the Visumax · 2020 | Their institution | $15,760 |
| Novartis Pharmaceuticals Corporation · A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study To Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 Mg/Ml and 15 Mg/Ml) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (Prk) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries · 2023 | Their institution | $13,610 |
| Allergan, Inc. · Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group Study of Agn-190584 for Participants With Presbyopia · 2020 | Their institution | $10,924 |
| Johnson & Johnson Surgical Vision, Inc. · A Non-Treatment Clinical Evaluation of the Docking Procedure Using Cheetah Beta 2a System and Cheetah Patient Interface · 2020 | This clinician | $9,600 |
| Glaukos Corporation · A Phase III, Multi-Center Study To Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus · 2020 | Their institution | $9,105 |
| Carl Zeiss Meditec, Inc. · A Prospective Randomized Comparison of Fellow Eyes Undergoing Lasik With Intralase Ifs 150 Versus the Visumax · 2021 | Their institution | $5,120 |
| Glaukos Corporation · A Phase IV Observational Registry To Assess the Safety and Durability of Effect of Corneal Collagen Cross-Linking With Photrexa Viscous, Photrexa, and the Kxl System in Patients With Corneal Ectasia Following Refractive Surgery · 2021 | Their institution | $3,525 |
| Allergan Inc. · Agn-199201 for the Treatment of Erythema With Rosacea · 2019 | Their institution | $3,000 |
| Allergan Inc. · Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group Study of Agn-190584 for Participants With Presbyopia · 2019 | Their institution | $2,859 |
| Glaukos Corporation · A Phase IV Observational Registry To Assess the Safety and Durability of Effect of Corneal Collagen Cross-Linking With Photrexa Viscous, Photrexa, and the Kxl System in Patients With Corneal Ectasia Following Refractive Surgery · 2020 | Their institution | $2,690 |
| GLAUKOS CORPORATION · 2022 | Their institution | $1,815 |
| Glaukos Corporation · Observational Registry To Assess the Durability of Effect of Corneal Colagen Cross-Linking · 2021 | Their institution | $600 |
| Novartis Pharmaceuticals Corporation · A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study To Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 Mg/Ml and 15 Mg/Ml) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (Prk) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries · 2024 | Their institution | $488 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1992863443
- Licence
- CA G17270California G17270: Current · expires 2027-08-31
- Trained
- Albert Einstein College of Medicine of Yeshiva University, 1996
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0120X (207WX0120X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2006-12-05
- NPI last updated
- 2024-04-04
- NPI record certified
- 2024-04-04
This is when the NPI record was last certified, not a medical board exam.